Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13606188 | 0.97 | SIGMAR1 (0.59) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL128294 | 0.97 | SIGMAR1 (0.59) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL13606187 | 0.97 | SIGMAR1 (0.59) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL11510150 | 0.97 | SIGMAR1 (0.59) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL15105362 | 0.97 | SIGMAR1 (0.59) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL15105416 | 0.97 | SIGMAR1 (0.59) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL13606194 | 0.97 | SIGMAR1 (0.59) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL9998889 | 0.97 | SIGMAR1 (0.59) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL7646991 | 0.97 | SIGMAR1 (0.59) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL13606190 | 0.97 | SIGMAR1 (0.59) | MAOAMAOBSIGMAR1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119877273-A | Carbon fiber sizing agent matched with (poly) dicyclopentadiene and application thereof | 吉林大学 | 2025-04-25 | — | — | CN | disclosed |
| US-20240116075-A1 | SUBSTRATE, SELECTIVE FILM DEPOSITION METHOD, DEPOSITION FILM OF ORGANIC MATTER, AND ORGANIC MATTER | CENTRAL GLASS COMPANY, LIMITED (JP) | 2024-04-11 | — | — | US | disclosed |
| CN-113149883-B | Process for preparing pyrrole compounds | 武田药品工业株式会社 | 2024-04-02 | — | — | CN | disclosed |
| EP-4287240-A1 | SUBSTRATE, SELECTIVE FILM DEPOSITION METHOD, DEPOSITION FILM OF ORGANIC MATTER, AND ORGANIC MATTER | Central Glass Company, Limited (JP) | 2023-12-06 | — | — | EP | disclosed |
| US-20230322669-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-4257577-A2 | METHOD FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2023-10-11 | — | — | EP | disclosed |
| US-11649206-B2 | Method for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-16 | — | — | US | disclosed |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | US | disclosed |
| US-20220411449-A1 | Method for Preparing Heteroleptic Triarylbismuthanes and Compounds Produced by the Same | UNIVERSITY OF HAWAII | 2022-12-29 | — | — | US | disclosed |
| EP-0480052-A1 | QUINOLINE DERIVATIVE, ANTIULCER DRUG CONTAINING THE SAME, AND PRODUCTION OF SAID DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| US-4576753-A | MICROBIOCIDES, ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-03-18 | — | — | US | disclosed |
| US-4478833-A | ANTICOAGULANTS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-10-23 | — | — | US | disclosed |
| US-4472300-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-09-18 | — | — | US | disclosed |
| US-4472309-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-09-18 | — | — | US | disclosed |
| US-4304718-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-08 | — | — | US | disclosed |
| US-4218309-A | HEAT TREATMENT OF PRODUCT FROM IN SITU RETORTING OF OIL SHALE | OCCIDENTAL RESEARCH CORPORATION (US) | 1980-08-19 | — | — | US | disclosed |
| US-4207234-A | 4-Unsubstituted azetidinone derivatives and process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-06-10 | — | — | US | disclosed |
| US-4181800-A | ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-01-01 | — | — | US | disclosed |
| US-3956345-A | POLYESTER | CIBA-GEIGY AG (CH) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411449-A1 | Method for Preparing Heteroleptic Triarylbismuthanes and Compounds Produced by the Same | COASY, HAGH, MRM1 | MAOA 373/4885MAOB 356/4885SIGMAR1 2160/4885 |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | MAOA 605/4885MAOB 500/4885SIGMAR1 3270/4885 |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | OTC, SLC38A7, SRI | MAOA 4/4885MAOB 8/4885SIGMAR1 248/4885 |
| US-20230322669-A1 | METHOD FOR PRODUCING PYRROLE COMPOUND | HPD, PPOX, CBR3 | MAOA 231/4885MAOB 234/4885SIGMAR1 3736/4885 |
| US-11649206-B2 | Method for producing pyrrole compound | HPD, PPOX, CBR3 | MAOA 231/4885MAOB 234/4885SIGMAR1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.